RU2502740C2 - Cdca1 эпитоп-пептиды и содержащие их вакцины - Google Patents

Cdca1 эпитоп-пептиды и содержащие их вакцины Download PDF

Info

Publication number
RU2502740C2
RU2502740C2 RU2011101709/10A RU2011101709A RU2502740C2 RU 2502740 C2 RU2502740 C2 RU 2502740C2 RU 2011101709/10 A RU2011101709/10 A RU 2011101709/10A RU 2011101709 A RU2011101709 A RU 2011101709A RU 2502740 C2 RU2502740 C2 RU 2502740C2
Authority
RU
Russia
Prior art keywords
hla
antigen
peptide
peptides
present
Prior art date
Application number
RU2011101709/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2011101709A (ru
Inventor
Такуя Цунода
Рюдзи ОХСАВА
Сатико Йосимура
Original Assignee
Онкотерапи Сайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапи Сайенс, Инк. filed Critical Онкотерапи Сайенс, Инк.
Publication of RU2011101709A publication Critical patent/RU2011101709A/ru
Application granted granted Critical
Publication of RU2502740C2 publication Critical patent/RU2502740C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2011101709/10A 2008-06-19 2009-06-18 Cdca1 эпитоп-пептиды и содержащие их вакцины RU2502740C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7406208P 2008-06-19 2008-06-19
US61/074,062 2008-06-19
US19759908P 2008-10-28 2008-10-28
US61/197,599 2008-10-28
PCT/JP2009/002771 WO2009153992A1 (en) 2008-06-19 2009-06-18 Cdca1 epitope peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
RU2011101709A RU2011101709A (ru) 2012-07-27
RU2502740C2 true RU2502740C2 (ru) 2013-12-27

Family

ID=41433910

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011101709/10A RU2502740C2 (ru) 2008-06-19 2009-06-18 Cdca1 эпитоп-пептиды и содержащие их вакцины

Country Status (16)

Country Link
US (2) US9387238B2 (enExample)
EP (1) EP2303912B1 (enExample)
JP (1) JP5640262B2 (enExample)
KR (2) KR20160119264A (enExample)
CN (1) CN102119171B (enExample)
AU (1) AU2009261382B2 (enExample)
BR (1) BRPI0914782B1 (enExample)
CA (1) CA2728268C (enExample)
DK (1) DK2303912T3 (enExample)
ES (1) ES2658842T3 (enExample)
IL (1) IL209967A (enExample)
MX (1) MX2010014044A (enExample)
RU (1) RU2502740C2 (enExample)
SG (1) SG191680A1 (enExample)
TW (1) TWI526219B (enExample)
WO (1) WO2009153992A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2699543C2 (ru) * 2014-08-04 2019-09-06 Онкотерапи Сайенс, Инк. Пептид, полученный из cdca1, и содержащая его вакцина
RU2809113C2 (ru) * 2018-02-21 2023-12-06 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Универсальные антигенпрезентирующие клетки и их применения

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
ES2537323T3 (es) 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2013071154A1 (en) * 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
ES2900004T3 (es) 2013-08-05 2022-03-15 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024766A1 (ja) * 2002-09-12 2004-03-25 Oncotherapy Science, Inc. Kdrペプチド及びこれを含むワクチン
WO2004080148A2 (en) * 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
EA008026B1 (ru) * 2003-01-30 2007-02-27 СУРВАК АпС Производные от сурвивина пептиды и их применение

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
EP0983357A1 (en) 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1196565A2 (en) 1999-06-30 2002-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AR031250A1 (es) 2000-07-11 2003-09-17 Corixa Corp Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2003025010A2 (en) 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
EP1519736A2 (en) 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN1703522A (zh) 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
US20040224408A1 (en) 2002-12-10 2004-11-11 Jean-Philippe Girard THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
TW200533376A (en) 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
WO2007013480A2 (en) 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
US7776341B2 (en) 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
UA100127C2 (ru) 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
ES2537323T3 (es) * 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2872532A4 (en) * 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024766A1 (ja) * 2002-09-12 2004-03-25 Oncotherapy Science, Inc. Kdrペプチド及びこれを含むワクチン
WO2004080148A2 (en) * 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
EA008026B1 (ru) * 2003-01-30 2007-02-27 СУРВАК АпС Производные от сурвивина пептиды и их применение

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARAO, MICHIKO ET AL., CDCA1, a novel cancer-testis antigen useful for immunotherapy of lung cancer, J. JAPAN SURGICAL SOCIETY, 2008, v.109, n. SUPP. 2, p.282. *
HARAO, MICHIKO ET AL., CDCA1, a novel cancer-testis antigen usefulfor immunotherapy of lung cancer, J. JAPAN SURGICAL SOCIETY, 2008, v.109, n. SUPP. 2, p.282. *
HARAO, MICHIKO, Cell division cycle associated 1, an ideal lung cancer antigen for immunotherapy, identified using cDNA microarray analysis, DOCTOR S THESIS, GRADUATE SCHOOL OF MEDICAL SCIENCES, March 2008. KUMAMOTO UNIVERSITY, KUMAMOTO, JAPAN. *
HARAO, MICHIKO, Cell division cycle associated 1, an ideal lung cancer antigen for immunotherapy, identified using cDNA microarray analysis, DOCTOR′S THESIS, GRADUATE SCHOOL OF MEDICAL SCIENCES, March 2008. KUMAMOTO UNIVERSITY, KUMAMOTO, JAPAN. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2699543C2 (ru) * 2014-08-04 2019-09-06 Онкотерапи Сайенс, Инк. Пептид, полученный из cdca1, и содержащая его вакцина
RU2809113C2 (ru) * 2018-02-21 2023-12-06 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Универсальные антигенпрезентирующие клетки и их применения

Also Published As

Publication number Publication date
JP2011524737A (ja) 2011-09-08
MX2010014044A (es) 2011-03-03
US10711047B2 (en) 2020-07-14
WO2009153992A1 (en) 2009-12-23
RU2011101709A (ru) 2012-07-27
IL209967A (en) 2015-09-24
SG191680A1 (en) 2013-07-31
EP2303912B1 (en) 2018-01-03
JP5640262B2 (ja) 2014-12-17
US9387238B2 (en) 2016-07-12
BRPI0914782A2 (pt) 2016-07-26
CA2728268A1 (en) 2009-12-23
KR20160119264A (ko) 2016-10-12
KR101705011B1 (ko) 2017-02-23
US20110189214A1 (en) 2011-08-04
BRPI0914782B1 (pt) 2021-08-31
KR20110031314A (ko) 2011-03-25
DK2303912T3 (en) 2018-03-12
TWI526219B (zh) 2016-03-21
TW201000120A (en) 2010-01-01
ES2658842T3 (es) 2018-03-12
AU2009261382B2 (en) 2013-08-15
EP2303912A4 (en) 2012-08-29
CA2728268C (en) 2017-11-07
US20160272692A1 (en) 2016-09-22
EP2303912A1 (en) 2011-04-06
AU2009261382A1 (en) 2009-12-23
IL209967A0 (en) 2011-02-28
CN102119171B (zh) 2014-08-06
CN102119171A (zh) 2011-07-06

Similar Documents

Publication Publication Date Title
RU2498993C2 (ru) Пептиды тем8 и содержащие их вакцины
US10711047B2 (en) CDCA1 epitope peptides and vaccines containing the same
US20110280898A1 (en) Inhbb epitope peptides and vaccines containing the same
RU2496787C2 (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
US9193765B2 (en) Melk epitope peptides and vaccines containing the same
MX2011001883A (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
RU2514386C2 (ru) Пептиды эпитопа wdrpuh и вакцины, содержащие их
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1156341B (en) Melk epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 36-2013 FOR TAG: (57)